扩散加权MRI与乳腺X线联合超声检测新诊断乳腺癌对侧隐匿癌的比较
本研究回顾性纳入1148例单侧新诊断乳腺癌且对侧无临床异常的女性,比较3T扩散加权MRI(DWI)与乳腺X线联合全乳超声检测对侧临床隐匿癌的效能。DWI检出率2.0%,显著高于联合检查的1.0%(p=0.009),且阳性预测值更高(42.1% vs 18.5%,p=0.001)。
要点
- DWI对对侧临床隐匿乳腺癌的检出率显著高于乳腺X线联合超声。
- DWI在推荐活检的患者中癌检出比例(PPV2)更高,减少不必要活检。
- 联合检查检出的癌症除2例DCIS外均被DWI检出。
核心结论
- 在新诊断乳腺癌女性中,DWI检出对侧乳腺癌的数量显著多于乳腺X线联合全乳超声,且活检推荐更少。
研究设计与样本
- 回顾性研究,纳入2017年1月至2018年7月共1148例单侧乳腺癌且对侧无临床异常的女性,平均年龄53.2±10.8岁,均行3T MRI(DWI b=1000 s/mm²及ADC图)、数字乳腺X线和放射科医师操作的全乳超声。
- 三位放射科医师独立盲法阅片评估对侧乳腺DWI并赋予BI-RADS分类;联合乳腺X线和超声采用前瞻性评估结果。
- 以组织病理学或1年随访为参考标准。
诊断标准与关键数值
- DWI检出30例临床隐匿对侧癌中的23例(76.7%),包括11例浸润癌和12例DCIS;联合乳腺X线和超声检出12例(40.0%),包括5例浸润癌和7例DCIS。
- DWI癌检出率为2.0%(95%CI:1.3%,3.0%),高于联合检查的1.0%(95%CI:0.5%,1.8%),p=0.009。
- DWI的PPV2为42.1%(95%CI:26.3%,59.2%),高于联合检查的18.5%(95%CI:9.9%,30.0%),p=0.001。
临床应用与阅片要点
- 对侧乳腺DWI可作为新诊断乳腺癌患者评估对侧隐匿癌的补充手段,尤其当乳腺X线和超声阴性时。
- DWI阅片时需结合b=1000 s/mm²和ADC图,按BI-RADS分类,注意DCIS也可能表现为扩散受限。
- 联合检查检出的癌症除2例DCIS外均被DWI检出,提示DWI漏诊风险较低,但仍需注意假阳性。
局限性
- 回顾性研究。
- 联合乳腺X线和超声采用前瞻性评估结果,而DWI为回顾性盲法阅片,评估方式不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the screening performance of diffusion-weighted (DW) MRI and combined mammography and ultrasound (US) in detecting clinically occult contralateral breast cancer in women with newly diagnosed breast cancer.
MATERIALS AND METHODS: Between January 2017 and July 2018, 1148 women (mean age ± standard deviation, 53.2 ± 10.8 years) with unilateral breast cancer and no clinical abnormalities in the contralateral breast underwent 3T MRI, digital mammography, and radiologist-performed whole-breast US. In this retrospective study, three radiologists independently and blindly reviewed all DW MR images (b = 1000 s/mm² and apparent diffusion coefficient map) of the contralateral breast and assigned a Breast Imaging Reporting and Data System category. For combined mammography and US evaluation, prospectively assessed results were used. Using histopathology or 1-year follow-up as the reference standard, cancer detection rate and the patient percentage with cancers detected among all women recommended for tissue diagnosis (positive predictive value; PPV₂) were compared.
RESULTS: Of the 30 cases of clinically occult contralateral cancers (13 invasive and 17 ductal carcinoma in situ [DCIS]), DW MRI detected 23 (76.7%) cases (11 invasive and 12 DCIS), whereas combined mammography and US detected 12 (40.0%, five invasive and seven DCIS) cases. All cancers detected by combined mammography and US, except two DCIS cases, were detected by DW MRI. The cancer detection rate of DW MRI (2.0%; 95% confidence interval [CI]: 1.3%, 3.0%) was higher than that of combined mammography and US (1.0%; 95% CI: 0.5%, 1.8%; p = 0.009). DW MRI showed higher PPV₂ (42.1%; 95% CI: 26.3%, 59.2%) than combined mammography and US (18.5%; 95% CI: 9.9%, 30.0%; p = 0.001).
CONCLUSION: In women with newly diagnosed breast cancer, DW MRI detected significantly more contralateral breast cancers with fewer biopsy recommendations than combined mammography and US.
引用
- Ha SM, Chang JM, Lee SH, et al. Detection of Contralateral Breast Cancer Using Diffusion-Weighted Magnetic Resonance Imaging in Women with Newly Diagnosed Breast Cancer: Comparison with Combined Mammography and Whole-Breast Ultrasound. Korean J Radiol. 2021. PMID: 33856137. doi:10.3348/kjr.2020.1183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。